(Reuters) -Hims & Hers Health said on Wednesday it is launching a new category in men’s health, offering access to personalized treatment plans for low testosterone.
Hims said it will expand its offerings in the segment in 2026 with the launch of Marius Pharmaceuticals’ oral testosterone Kyzatrex.
Kyzatrex, which received the U.S. Food and Drug Administration’s nod in 2022, has shown to restore testosterone levels in up to 96% of men, according to Hims.
The telehealth platform said it will also introduce access to injectable testosterone treatments in 2026.
The company had previously said that it plans to enter the market for low testosterone and menopause treatments and is looking at offerings to improve longevity and sleep.
Hims & Hers flourished over the last year when a shortage of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound allowed them to sell mass quantities of compounded versions of these weight-loss drugs.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Comments